QQQ   290.66 (-1.89%)
AAPL   143.26 (-1.83%)
MSFT   243.47 (-1.89%)
META   147.16 (-3.02%)
GOOGL   97.10 (-2.28%)
AMZN   100.64 (-1.56%)
TSLA   167.51 (-5.84%)
NVDA   192.52 (-5.47%)
NIO   12.06 (-5.11%)
BABA   111.50 (-5.81%)
AMD   72.67 (-3.62%)
T   20.19 (+1.20%)
MU   62.04 (-2.87%)
F   12.90 (-2.79%)
CGC   2.85 (-2.73%)
GE   80.97 (-2.72%)
DIS   107.73 (-1.65%)
AMC   5.05 (-8.35%)
PFE   43.49 (-0.69%)
PYPL   79.92 (-2.33%)
NFLX   353.86 (-1.92%)
QQQ   290.66 (-1.89%)
AAPL   143.26 (-1.83%)
MSFT   243.47 (-1.89%)
META   147.16 (-3.02%)
GOOGL   97.10 (-2.28%)
AMZN   100.64 (-1.56%)
TSLA   167.51 (-5.84%)
NVDA   192.52 (-5.47%)
NIO   12.06 (-5.11%)
BABA   111.50 (-5.81%)
AMD   72.67 (-3.62%)
T   20.19 (+1.20%)
MU   62.04 (-2.87%)
F   12.90 (-2.79%)
CGC   2.85 (-2.73%)
GE   80.97 (-2.72%)
DIS   107.73 (-1.65%)
AMC   5.05 (-8.35%)
PFE   43.49 (-0.69%)
PYPL   79.92 (-2.33%)
NFLX   353.86 (-1.92%)
QQQ   290.66 (-1.89%)
AAPL   143.26 (-1.83%)
MSFT   243.47 (-1.89%)
META   147.16 (-3.02%)
GOOGL   97.10 (-2.28%)
AMZN   100.64 (-1.56%)
TSLA   167.51 (-5.84%)
NVDA   192.52 (-5.47%)
NIO   12.06 (-5.11%)
BABA   111.50 (-5.81%)
AMD   72.67 (-3.62%)
T   20.19 (+1.20%)
MU   62.04 (-2.87%)
F   12.90 (-2.79%)
CGC   2.85 (-2.73%)
GE   80.97 (-2.72%)
DIS   107.73 (-1.65%)
AMC   5.05 (-8.35%)
PFE   43.49 (-0.69%)
PYPL   79.92 (-2.33%)
NFLX   353.86 (-1.92%)
QQQ   290.66 (-1.89%)
AAPL   143.26 (-1.83%)
MSFT   243.47 (-1.89%)
META   147.16 (-3.02%)
GOOGL   97.10 (-2.28%)
AMZN   100.64 (-1.56%)
TSLA   167.51 (-5.84%)
NVDA   192.52 (-5.47%)
NIO   12.06 (-5.11%)
BABA   111.50 (-5.81%)
AMD   72.67 (-3.62%)
T   20.19 (+1.20%)
MU   62.04 (-2.87%)
F   12.90 (-2.79%)
CGC   2.85 (-2.73%)
GE   80.97 (-2.72%)
DIS   107.73 (-1.65%)
AMC   5.05 (-8.35%)
PFE   43.49 (-0.69%)
PYPL   79.92 (-2.33%)
NFLX   353.86 (-1.92%)
NASDAQ:ARWR

Arrowhead Pharmaceuticals - ARWR Price Target & Analyst Ratings

$33.41
-0.20 (-0.60%)
(As of 01/30/2023 04:04 PM ET)
Add
Compare
Today's Range
$32.88
$33.80
50-Day Range
$28.00
$40.56
52-Week Range
$26.81
$56.25
Volume
486,959 shs
Average Volume
1.11 million shs
Market Capitalization
$3.57 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$59.22

Arrowhead Pharmaceuticals Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 9 Analyst Ratings

Consensus Analyst Price Target

$59.22
77.26% Upside
High Prediction$90.00
Average Prediction$59.22
Low Prediction$31.00
TypeCurrent
1/30/22 to 1/30/23
1 Month Ago
12/31/21 to 12/31/22
3 Months Ago
11/1/21 to 11/1/22
1 Year Ago
1/30/21 to 1/30/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
7 Buy rating(s)
7 Buy rating(s)
4 Buy rating(s)
5 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$59.22$62.67$66.57$90.83
Predicted Upside77.26% Upside100.39% Upside56.60% Upside33.21% Upside
Get Arrowhead Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter.


ARWR Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ARWR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Arrowhead Pharmaceuticals Stock vs. The Competition

TypeArrowhead PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.78
2.64
2.46
Consensus RatingModerate BuyBuyHold
Predicted Upside75.79% Upside955.88% Upside10.70% Upside
News Sentiment RatingPositive News
Positive News
Neutral News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
1/10/2023Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$82.00 ➝ $60.00+98.15%
1/9/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$64.00 ➝ $55.00+79.86%
12/6/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Patrick Trucchio
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy$110.00 ➝ $90.00+182.84%
11/30/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$65.00 ➝ $66.00+118.11%
11/30/2022B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$65.00 ➝ $59.00+96.73%
11/29/2022Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$92.00 ➝ $75.00+150.00%
11/29/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight$41.00 ➝ $37.00+32.14%
11/29/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetMarket Perform$33.00 ➝ $31.00+10.71%
5/11/2022Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Outperform$71.00 ➝ $60.00+74.98%
4/1/2022Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
P. Agrawal
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight
2/8/2021Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$90.00 ➝ $110.00+24.27%
12/15/2020UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$95.00+24.26%
11/24/2020Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetPositive ➝ Outperform$62.00 ➝ $80.00+27.92%
11/19/2020Smith Barney Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$90.00+30.02%
5/8/2020Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Esther Rajavelu
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$58.00+65.10%
(Data available from 1/30/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












ARWR Price Target - Frequently Asked Questions

What is Arrowhead Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 9 analysts in the last year, the consensus rating for Arrowhead Pharmaceuticals stock is Moderate Buy based on the current 2 hold ratings and 7 buy ratings for ARWR. The average twelve-month price prediction for Arrowhead Pharmaceuticals is $59.22 with a high price target of $90.00 and a low price target of $31.00. Learn more on ARWR's analyst rating history.

Do Wall Street analysts like Arrowhead Pharmaceuticals more than its competitors?

Analysts like Arrowhead Pharmaceuticals more than other Medical companies. The consensus rating for Arrowhead Pharmaceuticals is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how ARWR compares to other companies.

Does Arrowhead Pharmaceuticals's stock price have much upside?

According to analysts, Arrowhead Pharmaceuticals's stock has a predicted upside of 95.10% based on their 12-month price targets.

What analysts cover Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals has been rated by B. Riley, Chardan Capital, HC Wainwright, Jefferies Financial Group, Morgan Stanley, Piper Sandler, SVB Leerink, and The Goldman Sachs Group in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:ARWR) was last updated on 1/30/2023 by MarketBeat.com Staff